Why the study?
Are serum thrombopoietin (TPO) levels different between patients with amegakaryocytic thrombocytopenia and immune thrombocytopenic purpura?
Are serum thrombopoietin (TPO) levels different between patients with amegakaryocytic thrombocytopenia and immune thrombocytopenic purpura?
Serum TPO levels are markedly elevated in amegakaryocytic thrombocytopenia compared to immune thrombocytopenic purpura, suggesting TPO levels may be regulated by megakaryocyte counts.
This is the authors' abstract. We don't add key points for this paper.
We assayed serum thrombopoietin (TPO) levels in amegakaryocytic thrombocytopenia (AMT) and immune thrombocytopenic purpura (ITP) patients by using a newly established enzyme-linked immunosorbent assay (ELISA). TPO levels in AMT patients were quite high (mean +/- SD = 13.7 +/- 11.2 fmoles/ml, n = 4), whereas those in ITP patients were only slightly higher (1.25 +/- 0.39, n = 12) than those of the healthy donors (0.55 +/- 0.2, n = 20). Furthermore, in ITP patients no correlation was observed between platelet counts and serum TPO levels (correlation coefficient = 0.14). We further assayed serum TPO levels sequentially during steroid treatment in patients with AMT and ITP. In one AMT patient serum TPO levels started to decrease in accordance with the increase of megakaryocyte counts, which preceded the increase in platelet counts. However, in ITP patients serum TPO levels did not change significantly throughout the course of the treatment despite the recovery of platelet counts. Based on these findings, we conclude that serum TPO levels may be regulated at least in part by megakaryocyte counts.
Answers are grounded in this paper and cite their sources.
May aid AMT-ITP differentiation in thrombocytopenia; leaves open diagnostic utility and megakaryocyte regulation.
No takes yet. Share an insight, caveat, or question.
Mukai et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: